Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 93.3% in the 1st quarter, Holdings Channel reports. The institutional investor owned 254,373 shares of the company’s stock after acquiring an additional 122,773 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Amneal Pharmaceuticals were worth $3,162,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Spire Wealth Management lifted its position in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after purchasing an additional 1,159 shares during the last quarter. Hsbc Holdings PLC grew its holdings in shares of Amneal Pharmaceuticals by 1.6% during the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after purchasing an additional 1,569 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the last quarter. Finally, Comerica Bank increased its position in shares of Amneal Pharmaceuticals by 56.1% during the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Key Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations. Amneal reported $796 million in second-quarter revenue, $58 million in GAAP net income, and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus. GAAP diluted EPS was $0.18. Revenue and earnings also improved from the year-ago period. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability was stronger than anticipated. Adjusted EBITDA reached $206 million, while reported earnings exceeded Wall Street forecasts. The results helped drive an initial sharp advance in AMRX shares after the release. Amneal Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Amneal raised or reaffirmed a constructive 2026 outlook. Full-year revenue guidance is $3.1 billion to $3.2 billion, and EPS guidance is $0.96 to $1.06, with the EPS midpoint above the current consensus estimate. The company also completed a July debt repricing expected to reduce interest costs. Amneal Pharmaceuticals Earnings and Guidance
• Neutral Sentiment: Management’s earnings call provided additional context. Investors are evaluating the sustainability of the quarterly beat, the updated guidance, and the expected benefit from lower financing costs. Amneal Q2 2026 Earnings Call Transcript
• Negative Sentiment: Some of the initial earnings enthusiasm faded. After the sharp post-results rally, investors may have locked in gains, particularly because the revenue outlook was approximately in line with expectations rather than a major upside surprise.
• Negative Sentiment: Balance-sheet and return metrics remain risks. Amneal’s reported net margin was only 4.01%, and return on equity remained deeply negative, which could limit valuation expansion despite improving operating results.

Amneal Pharmaceuticals Trading Down 3.1%

Shares of AMRX stock opened at $18.50 on Friday. The company has a market cap of $5.90 billion, a price-to-earnings ratio of 48.69 and a beta of 1.26. The stock has a 50 day simple moving average of $16.11 and a 200-day simple moving average of $14.23. Amneal Pharmaceuticals, Inc. has a 12-month low of $7.66 and a 12-month high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.03. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. Finally, UBS Group raised their target price on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.